Semanext/ Livarise
by Lupin (via Zydus) · DCGI approved March 2026
| Active ingredient | Semaglutide (GLP-1 receptor agonist) |
| Indication | Type 2 Diabetes + Obesity |
| Manufacturer | Lupin Limited |
| DCGI status | Approved March 2026 |
| Price (MRP) | ₹2,200/month |
| Format | Reusable pen Same Zydus reusable-pen platform as Semaglyn |
| Prescription | Schedule H — required |
How Semanext compares
Semanext is Lupin's brand of generic semaglutide, manufactured under licence from Zydus on the same reusable-pen platform as Semaglyn. Lupin's strength is its commercial reach into endocrinology and pulmonology prescribers, particularly in Western and Northern India. Livarise is Lupin's sister brand for parallel channel coverage.
About Lupin (via Zydus)
Lupin is India's third-largest pharma exporter and has historically focused on respiratory and CNS franchises. Its semaglutide entry via the Zydus platform avoids the manufacturing-scale-up timeline its competitors face, accelerating time-to-market.
Manufacturer announcement
Additional source
Pearce IP — generic semaglutide India launchesGLP-1 Check is informational, not a medical diagnosis. Semaglutide is a Schedule H drug in India and requires a prescription from a registered medical practitioner. Always consult a qualified physician before starting any treatment.